Foreign investors often look at Vietnam through familiar lenses: manufacturing, exports, infrastructure, renewable energy, real estate, and digital transformation.
Yet one of Vietnam’s most compelling future investment stories may come from a very different source: its biodiversity.
Vietnam is one of the most biologically diverse countries in Asia. Its ecosystems include tropical forests, wetlands, marine resources, endemic species, medicinal plants, microorganisms, fungi, agricultural genetic resources, and traditional knowledge accumulated over generations. For a long time, these assets were viewed mainly from the perspective of conservation.
That view is too narrow.
In the age of biotechnology, biodiversity is no longer only an environmental asset. It can become innovation capital.
The question for investors is therefore not merely how Vietnam protects biodiversity. The more interesting question is how Vietnam can responsibly transform its biodiversity into scientific, commercial, and technological value.
Vietnam’s Law on Biodiversity provides an important starting point. It does not only regulate conservation. It also creates a legal framework for access to genetic resources, benefit-sharing, scientific research, commercialization, biodiversity conservation facilities, genetic specimen storage, and the allocation of intellectual property rights arising from innovation based on genetic resources.
For biotechnology investors, pharmaceutical companies, agritech groups, research institutions, and impact investors, this is highly relevant.
Vietnam’s legal framework expressly recognizes access to genetic resources for research, development, and the production of commercial products. It also requires benefit-sharing arrangements with the State and relevant parties. Importantly, it contemplates the distribution of intellectual property rights arising from invention results based on access to genetic resources and traditional knowledge.
This is where the investment story becomes particularly powerful.
Biodiversity can support the development of pharmaceuticals, nutraceuticals, cosmetics, agricultural biotechnology, biological crop protection, food technology, climate-resilient crops, diagnostics, and industrial biotechnology. In a world where healthcare resilience, sustainable agriculture, supply-chain diversification, and ESG-driven investment are becoming increasingly important, Vietnam’s biodiversity may represent a strategic advantage that remains underappreciated.
The opportunity is not without complexity. Investors must understand access permits, benefit-sharing contracts, restrictions on endangered species, conservation-zone rules, traditional knowledge rights, environmental impact requirements, and risk management for genetically modified organisms. But complexity should not be confused with impossibility. In many emerging sectors, a regulated framework is precisely what serious investors need.
Vietnam is not offering a lawless frontier. It is offering a structured pathway.
That matters.
The most attractive investment opportunities often arise when three elements meet: natural advantage, regulatory structure, and market demand. In biotechnology, Vietnam may increasingly have all three.
Its natural advantage lies in its biodiversity.
Its regulatory structure is found in the Law on Biodiversity and related implementing regulations.
Its market demand comes from rising healthcare needs, food security concerns, climate adaptation, sustainable agriculture, and the global search for new sources of innovation.
For decades, Vietnam’s economic transformation was written in factories, ports, industrial parks, and infrastructure projects. The next chapter may also be written in laboratories, research centers, gene banks, conservation facilities, and biotechnology partnerships.
This does not mean that Vietnam will become a biotechnology hub overnight. Such ecosystems require capital, talent, regulatory coordination, intellectual property protection, scientific institutions, and international partnerships. But investors who wait until a sector is already obvious often arrive too late.
The greatest opportunities are frequently visible first to those who understand the legal and regulatory foundations before the market fully prices them in.
Vietnam’s biodiversity is not only a national treasure. With the right investment, governance, science, and international cooperation, it may become a foundation for a new generation of biotechnology opportunities.
Foreign investors should pay attention.
The future of Vietnam’s growth story may not only be manufactured.
It may be discovered, sequenced, cultivated, protected, and commercialized through biotechnology.
The real question is this:
Will investors recognize Vietnam’s biodiversity advantage early enough
***
For more information on the above, please do not hesitate to contact the author Dr. Oliver Massmann under [email protected]. Dr. Oliver Massmann is the General Director of Duane Morris Vietnam LLC.
